Shattuck Labs Inc (STTK)

STTK...HERE WE GO

STTK...WEEKLY BIO BEAST

STTK........................................https://stockcharts.com/sc3/ui/?s=STTK&p=W&b=5&g=0&id=p86431144783

STTK.................................https://stockcharts.com/h-sc/ui?s=STTK&p=W&b=5&g=0&id=p86431144783

STTK.................................................https://stockcharts.com/h-sc/ui?s=STTK&p=W&b=5&g=0&id=p86431144783

Lets Go Get It STTK $$$$$

sttk..........................................................P/M

STTK HERE COMES 2.00

STTK...2.40 MAGNET.....NO...DO WE DARE

STTK...MINI MONSTER GETTING LOTS OF LOVE

STTK...HERE WE GO

STTK BUILDING MOMO

(STTK uses too) CD47
https://med.stanford.edu/news/all-news/2017/11/second-dont-eat-me-signal-found-on-cancer-cells.html

https://www.gilead.com/news/news-details/2020/gilead-to-acquire-forty-seven-for-49-billion

HAVE NO CLUE WHAT THAT MEANS

I used to love this - always love me some dont eat me

STTK LOW VOLUME MOVE....SO DILUTION OFF THE TABLE

STTK COMING OFF BOTTOM

STTK............................https://stockcharts.com/h-sc/ui?s=STTK&p=W&b=5&g=0&id=p86431144783

STTK under $4

absolutely revolutionary data in HR MDS... compare to SOC!!! HMAs show a ORR 30%, CR 10-20%
(also beats venetoclax + HMA in TP53m AML)

Observed 79% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete response (CR)/marrow complete response (mCR) rate of 64% –

– Observed 27% initial CR/complete response with incomplete hematologic recovery (CRi) in frontline TP53m AML patients, and 5/11 evaluable patients achieved stable disease with decreasing blast counts and peripheral blood count improvement, these patients continue on treatment

STTK new 52 week high

STTK new 52 week high

STTK new 52 week low

Takeda gonna tender on next trial fast track

load it-going to 10+

No fooling? So you say a 1.75% profit for a two-hour trade is a bad trade?

Bad trade

Ok. I got out of this POS this morning at $5.00, got lucky is all

@ 4.29 I was just looking for a move under $4 and it did

small gain, but I didnt know how many borrows I could get if it went against me

sometimes I go short, and get upside down and cant average up, because broker all of a sudden has NO available shares to short= your stuck

so thats why I dont short much

What price did you short?tia

I shorted it... Its just Phase 1

AI bot hyper extended the POP

I used to chase these Pase 1 rallys, lost lots of money doing so

some of my biggest losses ever

Phase 1 Gap & Traps

Did you see this open? $7.28! then immediately dropped down to $2.50 omg. I'm in at $3.00 just hoping for the best. Worth a shot

$STTK KEEP THIS ON WATCH! pic.twitter.com/6owPN2LcXn— Tiger Line Trading (@TigerLineTrades) December 13, 2023

$TSOI's new Introducing the ALScell™, also known as the JadiCell™ – Now, these ALScells are not your run-of-the-mill mesenchymal stem cells; they're basically the overachievers of the cellular world. These ALScells have it all – enhanced growth factor production, like they've been hitting the gym and drinking protein shakes on a regular basis. They can secrete exosomes , outshining their stem cell peers who are still trying to figure out how to tie their cellular shoelaces.

But wait, there's more! These ALScells are not just content with being academically gifted; they've got some serious street smarts too. Superior angiogenic and neurogenic abilities mean they're like the cool kids who not only excel in science class but also throw legendary parties in the cellular neighborhood.

And guess what? Exosomes are not just a fancy word; they're the VIP pass to the cure of many cancers. It's like the ALScells are hosting the party, and exosomes are the invitations that cancer cells can't resist.

So, say hello to the ALScell™ – the cellular superhero ready to save the day, one enhanced growth factor at a time, and unlocking cures like a boss!
Bullish
BULLISH

Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Pati

STTK under $2